Camrelizumab is a programmed cell death 1 (PD-1) inhibitor that was recently investigated as a treatment for various malignancies, including B cell lymphoma, Hodgkin lymphoma, HCC, gastric and gastroesophageal cancers, and nonsmall cell lung cancer. The gene discussed is PDCD1; the disease is B-cell non-Hodgkin lymphoma.